Sep 13, 2022 8:00 am EDT Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
Sep 12, 2022 9:00 am EDT Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 2, 2022 4:15 pm EDT Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022
Jul 27, 2022 8:00 am EDT Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
Jun 14, 2022 8:00 am EDT Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101
May 23, 2022 4:15 pm EDT Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program